Your browser doesn't support javascript.
loading
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19.
Peluso, Michael J; Kelly, J Daniel; Lu, Scott; Goldberg, Sarah A; Davidson, Michelle C; Mathur, Sujata; Durstenfeld, Matthew S; Spinelli, Matthew A; Hoh, Rebecca; Tai, Viva; Fehrman, Emily A; Torres, Leonel; Hernandez, Yanel; Williams, Meghann C; Arreguin, Mireya I; Bautista, Jennifer A; Ngo, Lynn H; Deswal, Monika; Munter, Sadie E; Martinez, Enrique O; Anglin, Khamal A; Romero, Mariela D; Tavs, Jacqueline; Rugart, Paulina R; Chen, Jessica Y; Sans, Hannah M; Murray, Victoria W; Ellis, Payton K; Donohue, Kevin C; Massachi, Jonathan A; Weiss, Jacob O; Mehdi, Irum; Pineda-Ramirez, Jesus; Tang, Alex F; Wenger, Megan; Assenzio, Melissa; Yuan, Yan; Krone, Melissa; Rutishauser, Rachel L; Rodriguez-Barraquer, Isabel; Greenhouse, Bryan; Sauceda, John A; Gandhi, Monica; Hsue, Priscilla Y; Henrich, Timothy J; Deeks, Steven G; Martin, Jeffrey N.
Afiliación
  • Peluso MJ; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Lu S; Department of Ophthalmology, University of California, San Francisco, USA.
  • Goldberg SA; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Davidson MC; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Mathur S; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Durstenfeld MS; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Spinelli MA; Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Hoh R; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Tai V; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Fehrman EA; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Torres L; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Hernandez Y; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Williams MC; Division of Experimental Medicine, University of California, San Francisco, USA.
  • Arreguin MI; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Bautista JA; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Ngo LH; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Deswal M; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Munter SE; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Martinez EO; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Anglin KA; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Romero MD; Division of Experimental Medicine, University of California, San Francisco, USA.
  • Tavs J; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Rugart PR; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Chen JY; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Sans HM; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Murray VW; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Ellis PK; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Donohue KC; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Massachi JA; Division of Experimental Medicine, University of California, San Francisco, USA.
  • Weiss JO; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Mehdi I; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Pineda-Ramirez J; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Tang AF; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Wenger M; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Assenzio M; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Yuan Y; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Krone M; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Rutishauser RL; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Rodriguez-Barraquer I; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Greenhouse B; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Sauceda JA; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Gandhi M; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
  • Hsue PY; Division of Experimental Medicine, University of California, San Francisco, USA.
  • Henrich TJ; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Deeks SG; Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
  • Martin JN; Center for AIDS Prevention Studies, University of California, San Francisco, USA.
medRxiv ; 2021 Mar 12.
Article en En | MEDLINE | ID: mdl-33758895
ABSTRACT

BACKGROUND:

As the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC).

METHODS:

From April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit.

RESULTS:

We have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR] 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits.

CONCLUSION:

Among a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: MedRxiv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: MedRxiv Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos